Check 35,000+ stocks against 26 valuation models and 37 quality factors

Starlake Bioscience Co Inc Zhaoqing Guangdong (600866) fair value: what the stock is really worth

As of Sep 24, 2026: fair value of Starlake Bioscience Co Inc Zhaoqing Guangdong ¥11.29, price ¥4.12, upside +174.0%, quality 41 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

Fair value above price? Yes
Good quality? No
Add to watchlist

Healthcare · CN · ISIN CNE000000H46

SB Thin data Sep 24, 2026

Starlake Bioscience Co Inc Zhaoqing Guangdong

600866 · SHG

Cheap, value-trap riskThe stock looks deeply undervalued, but low quality raises value-trap risk.

✓Fair value ¥11.29 · Strongly undervalued (+174%)

!Quality 41/100

!Weak Growth (revenue 5y +70.1 %/yr)

!Thin margins · 2.9% net margin (TTM)

!Low debt · negative free cash flow

·9.22% dividend yield

✓Ranks above peers (8/13)

!Narrow moat 28/100

!Evidence only low, so the estimate is less certain

!Weak on past: 21 out of 100

26 models, one by oneBear ¥8.01 to bull ¥14.58 Growth analysisrevenue history, year by year Quality 41/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Watch Starlake Bioscience Co Inc Zhaoqing Guangdong for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range ¥3.53 – ¥8.49 · fair‑value band ¥8.01 – ¥14.58 · the ¥4.12 price screens below the ¥11.29 fair value. Dashed = 300-day average. As of Sep 24, 2026.

Follow Starlake Bioscience Co Inc Zhaoqing Guangdong in your weekly email

Every Wednesday you see whether Starlake Bioscience Co Inc Zhaoqing Guangdong is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Star Lake Bioscience Co., Inc.Zhaoqing Guangdong engages in the manufacture and sale of pharmaceutical raw materials, and food and feed additives under the Star Lake and Yue Bao brand names in China and internationally. The company offers L-proline for use as an intermediate for synthesizing captopril and enalapril, and raw material for amino acid transfusion; guanosine that is used as an intermediate for food and pharmaceutical raw material; adefovir dipivoxil tablets used to reduce the activity of HBV DNA polymerase and anti-virus by destroying Hepatitis B virus DNA; and L-threonine that is used in premixtures, and pig and poultry feed. It also provides disodium 5'-ribonucleotide to cure chronic hepatitis, muscular atrophy, and eye diseases; disodium 5-inosinate to cure leukopenia, thrombocytopenia, and chronic and acute hepatitis; and inosine, which is used for the treatment of chronic and acute hepatitis, heart disease, leukopenia or thrombocytopenia, central choroidoretinitis, etc. In addition, the company offers disodium 5'-guanylate for canned and salted meat, ham, etc. Further, it provides ribavirin, adenosine, adenine, memantine hydrochloride, arginine, D-ribose, fructose syrup, L-valine, L-threonine, L-lysine, etc. Star Lake Bioscience Co., Inc.Zhaoqing Guangdong was founded in 1964 and is based in Zhaoqing, China.

Stock analysis

Starlake Bioscience Co Inc Zhaoqing Guangdong (600866) currently trades at ¥4.12, while our model-based Fair Value estimate is ¥11.29, implying the stock looks roughly 63.5% undervalued today.

Valuation

Bull case: the Growth Earnings group reads highest at a median of ¥15.61 per share, and 13 of the 14 models we run sit above the ¥4.12 price.

Bear case: the Asset-Based group reads lowest at ¥3.31, and 1 of the 14 models stay below the price. Evidence for this calculation is low.

Scenario range: ¥8.01 (bear) to ¥14.58 (bull), the price of ¥4.12 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 41/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Starlake Bioscience Co Inc Zhaoqing Guangdong reported revenue of 15.9B CNY in FY2025 versus 4.1B CNY in FY2021, a compound +40.6%/yr. Reported net income was 979M CNY in FY2025, compounding +59.3%/yr from FY2021. FY2021 was a trough year, so the rate overstates the trend.

Key figures

Market cap 6.8B CNY (≈ $1.0B) · P/E ratio 14.7 · P/S ratio 0.91 · EPS (TTM) ¥0.2800 · Dividend yield 9.2% · Net margin 6.2% · Return on equity 5.3% · Return on assets (EBIT) 8.5%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).

What moves the price

The share trades about 49% below its 52-week high and 1% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at 174%, 600866 screens cheaper than that median.

Fair Value models

Bear ¥8.01 Fair Value ¥11.29 Bull ¥14.58

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.

Highest evidence

EPV ¥4.72 ¥5.38 ¥5.93 74

Residual Income ¥4.30 ¥4.82 ¥7.62 73

ROIC Compounder ¥4.72 ¥5.94 ¥7.28 70

All 14 models by family

Earnings-Based

Graham-Dodd ¥4.01 ¥26.88 ¥37.66 61

Lynch FV ¥7.87 ¥11.24 ¥14.61 59

PEG = 1.0 ¥7.87 ¥11.24 ¥14.61 55

EPV ¥4.72 ¥5.38 ¥5.93 74

Multiples

P/E Multiple ¥9.28 ¥12.37 ¥15.47 63

P/S Multiple ¥7.51 ¥10.02 ¥12.52 58

P/B Multiple ¥7.51 ¥10.02 ¥12.52 55

EV/EBIT ¥9.76 ¥13.05 ¥16.34 66

EV/EBITDA ¥12.43 ¥16.61 ¥20.79 67

EV/Revenue ¥6.93 ¥9.95 ¥12.97 53

Asset-Based

NCAV (Graham) ¥2.47 ¥3.31 ¥4.95 54

Economic Profit

Residual Income ¥4.30 ¥4.82 ¥7.62 73

ROIC Compounder ¥4.72 ¥5.94 ¥7.28 70

Growth Earnings

Growth-Adj P/E ¥10.92 ¥15.61 ¥20.29 65

Open the full fair value analysis →

Notify me when 600866 reaches fair value

Put 600866 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 41/100

Of which business quality 43 · Market factors (momentum, volatility) 30

Profitability 45

Margins and returns on capital today

Quality Growth 33

Are margins and returns improving?

Cashflow 23

Earnings quality: real cash, not paper profit

Fin. Strength 58

Balance sheet, leverage, solvency risk

Investment 66

Disciplined investing over empire-building

Low Volatility 81

Calm price path (market factor)

Momentum 14

Price trend over the last 3–12 months (market factor)

52W Momentum 1

Distance to the 52-week high (market factor)

Net Issuance 40

Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 40/100

Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Revenue growth 1 year

−8.3%

Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

−3.1%

Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+70.1%

Start year 2020 (pandemic). Over 10 years: +36.1% a year

Revenue growth 31 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+14.1%

’14

’15

’16

’17

’18

’19

’20

’21

’22

’23

’24

’25

What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.

+33.2%

Earnings growth per share plus dividend.

Earnings per share, growth per year+24.0%

Dividend (yield on the price)9.2%

Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.24% vs 32%, slowing

Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.14% → 8%

Start year 2020 (pandemic)

Watch 600866, get fair value alerts →

Compare Starlake Bioscience Co Inc Zhaoqing Guangdong with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 654 stocks

Beats the industry median on 8/13 measures

Overall it ranks above its industry peers.

Valuation

Quality Score 41 · Below median

Fair Value upside +174% · Top 25%

Profitability

Return on equity (TTM) 5% · Above median

Return on assets 2% · Top 25%

Net margin (TTM) 3% · Below median

Operating margin (TTM) −1% · Below median

Growth and dividend

Revenue growth −7% · Below median

Dividend yield (TTM) 9.2% · Top 25%

Balance sheet

Debt / equity 0.29× · Highest 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/E (TTM) 14.7× · Cheaper than median

P/B 0.83× · Cheaper than median

P/S (TTM) 0.44× · Cheapest 25%

EV/EBITDA 5.2× · Cheapest 25%

Strength profile in five axes (Snowflake)

This stock

Sector peers

VALUE (fair-value potential)100 · sector 0

FUTURE (revenue growth)0 · sector 0

PAST (return on equity)21 · sector 0

HEALTH (low debt)86 · sector 97

DIVIDEND (yield)100 · sector 23

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX	$522.38	$574.62	+10%
Regeneron Pharmaceuticals, Inc REGN	$801.82	$1,252	+56%
argenx SE ARGX	$963.79	$918.60	−5%
Samsung Biologics Co 207940	1,366,000 KRW	1,502,600 KRW	+10%
CSL Limited CSL	A$179.12	A$197.03	+10%
Alnylam Pharmaceuticals, Inc ALNY	$251.65	$218.36	−13%
Royalty Pharma plc RPRX	$58.52	$24.22	−59%
BeOne Medicines AG 6160	HK$218.20	HK$169.72	−22%
Celltrion, Inc 068270	177,400 KRW	74,519 KRW	−58%
BioNTech SE BNTX	$100.87	$63.62	−37%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Run the numbers yourself: free valuation calculators

DCF Calculator Graham Number Peter Lynch Formula DDM Calculator Fama-French Model Intrinsic Value

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Starlake Bioscience Co Inc Zhaoqing Guangdong · Fair Value
¥11.29 +64%Fair Value
Calculator →

<a href="https://www.fairvalue-calculator.com/stock/600866" target="_blank" rel="nofollow noopener" style="display:inline-flex;align-items:center;gap:12px;box-sizing:border-box;font-family:system-ui,-apple-system,Segoe UI,Roboto,sans-serif;text-decoration:none;background:#0f1814;color:#eaf2ed;border:1px solid #2a3a30;border-radius:12px;padding:12px 16px;max-width:360px"><span style="line-height:1.35"><span style="font-size:12px;color:#9fb0a8">Starlake Bioscience Co Inc Zhaoqing Guangdong · Fair Value</span><br><b style="font-size:20px">¥11.29</b> <span style="color:var(--fvc-g-mitte);font-weight:700;font-size:14px">+64%</span></span><span style="font-size:11px;color:var(--fvc-g-mitte);font-weight:700;margin-left:auto;text-align:right;line-height:1.3">Fair&nbsp;Value<br>Calculator&nbsp;→</span></a>

Cite: Fair Value Calculator (2026). "Starlake Bioscience Co Inc Zhaoqing Guangdong Fair Value". https://www.fairvalue-calculator.com/stock/600866

Frequently asked questions

Is Starlake Bioscience Co Inc Zhaoqing Guangdong (600866) overvalued or undervalued?

As of Sep 24, 2026, our model estimates a fair value of ¥11.29 versus a price of ¥4.12, about +174% upside (undervalued).

What is the fair value of 600866?

Our model-based fair value for Starlake Bioscience Co Inc Zhaoqing Guangdong is ¥11.29 (as of Sep 24, 2026), built from audited fundamentals. The current price: ¥4.12.

What is the quality score of 600866?

Starlake Bioscience Co Inc Zhaoqing Guangdong has a Quality Score of 41/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for Starlake Bioscience Co Inc Zhaoqing Guangdong (600866)?

Our model-based price target is the fair value of ¥11.29 (as of Sep 24, 2026) from 14 valuation models. Cautious scenario ¥8.01, optimistic scenario ¥14.58. It is a calculation from audited fundamentals, not an analyst target.

What is the Starlake Bioscience Co Inc Zhaoqing Guangdong stock forecast for 2026?

Our models put fair value at ¥11.29, about +174% upside versus a price of ¥4.12 (undervalued). Cautious scenario ¥8.01, optimistic scenario ¥14.58. The calculation is refreshed regularly with new filings.

What is the revenue of Starlake Bioscience Co Inc Zhaoqing Guangdong (600866)?

Starlake Bioscience Co Inc Zhaoqing Guangdong reported trailing-twelve-month revenue of about 15.6B CNY (latest available figure, as of Sep 24, 2026).

Does Starlake Bioscience Co Inc Zhaoqing Guangdong pay a dividend?

Starlake Bioscience Co Inc Zhaoqing Guangdong currently shows a dividend yield of about 9.22% relative to its recent price (as of Sep 24, 2026).

What is the intrinsic value of Starlake Bioscience Co Inc Zhaoqing Guangdong (600866)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Starlake Bioscience Co Inc Zhaoqing Guangdong it is ¥11.29 per share (as of Sep 24, 2026), against a price of ¥4.12. It is the blended result of 14 valuation models (cash flow, earnings, asset, dividend).

Is Starlake Bioscience Co Inc Zhaoqing Guangdong stock overvalued or undervalued in 2026?

As of Sep 24, 2026, 600866 trades below its calculated fair value: price ¥4.12, fair value ¥11.29, a gap of about +174% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of 600866?

No. The price is what the market pays today (¥4.12); the fair value is what the company's own numbers justify (¥11.29). For Starlake Bioscience Co Inc Zhaoqing Guangdong the two are ¥7.17 per share apart. That gap is exactly why we show both numbers side by side.

How much is Starlake Bioscience Co Inc Zhaoqing Guangdong worth?

The market values Starlake Bioscience Co Inc Zhaoqing Guangdong at about 6.8B CNY (market capitalisation, as of Sep 24, 2026). Per share that is ¥4.12; our models calculate a fair value of ¥11.29 per share.

What do the bullish and bearish scenarios say about 600866?

Our models span a range for Starlake Bioscience Co Inc Zhaoqing Guangdong: cautious scenario ¥8.01, base ¥11.29, optimistic ¥14.58 per share (as of Sep 24, 2026, price ¥4.12). The range comes from different growth and margin assumptions, not from analyst opinions.

What is the P/E ratio of 600866?

Starlake Bioscience Co Inc Zhaoqing Guangdong trades at a price-to-earnings ratio of 14.7 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥11.29 is built from several models across several years. Other multiples: P/B 0.8, P/S 0.4, EV/EBITDA 5.2.

How solid is the balance sheet of Starlake Bioscience Co Inc Zhaoqing Guangdong (600866)?

Balance-sheet figures for Starlake Bioscience Co Inc Zhaoqing Guangdong (as of Sep 24, 2026): return on equity 5.3%, debt of 0.29 per unit of equity. They feed the Quality Score of 41/100, which measures business quality independently of the share price.

How far is 600866 from its 52-week high?

Starlake Bioscience Co Inc Zhaoqing Guangdong trades at ¥4.12, about 49% below its 52-week high of ¥8.13 and 1% above the low of ¥4.06 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of ¥11.29 is for.

Which stocks are comparable to Starlake Bioscience Co Inc Zhaoqing Guangdong?

From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is Starlake Bioscience Co Inc Zhaoqing Guangdong stock attractive at the current price?

The data as of Sep 24, 2026: price ¥4.12, calculated fair value ¥11.29 (+174%), Quality Score 41/100, from 14 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

How is the fair value of 600866 calculated?

We run Starlake Bioscience Co Inc Zhaoqing Guangdong through 14 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥11.29, with the spread shown as a cautious and an optimistic scenario.

Is it still worth investing in stocks now?

The global stock market currently sits 14.0 % above its aggregate fair value. Starlake Bioscience Co Inc Zhaoqing Guangdong currently trades 174 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of Starlake Bioscience Co Inc Zhaoqing Guangdong (600866)?

The closing price on Sep 24, 2026 was ¥4.12. Our model-based fair value is ¥11.29, about +174% upside (undervalued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with Starlake Bioscience Co Inc Zhaoqing Guangdong right now?

The large discount to fair value meets weak quality (41/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case (¥8.01). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (¥8.01 to ¥14.58) leaves room in how you read the outcome.

Key figures of Starlake Bioscience Co Inc Zhaoqing Guangdong

How large is the market capitalisation of Starlake Bioscience Co Inc Zhaoqing Guangdong (600866)?

The market capitalisation of Starlake Bioscience Co Inc Zhaoqing Guangdong is 6.8B CNY (≈ $1.0B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What is the P/S ratio of Starlake Bioscience Co Inc Zhaoqing Guangdong (600866)?

The price-to-sales ratio of Starlake Bioscience Co Inc Zhaoqing Guangdong is 0.91 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.

What are the earnings per share of Starlake Bioscience Co Inc Zhaoqing Guangdong (600866)?

Earnings per share at Starlake Bioscience Co Inc Zhaoqing Guangdong are ¥0.2800 (price ÷ EPS = P/E 14.7). Earnings per share over the last twelve months: total profit spread across every single share.

What is the dividend yield of Starlake Bioscience Co Inc Zhaoqing Guangdong (600866)?

The dividend yield of Starlake Bioscience Co Inc Zhaoqing Guangdong is 9.2% (payout 136%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.

What is the net margin of Starlake Bioscience Co Inc Zhaoqing Guangdong (600866)?

The net margin of Starlake Bioscience Co Inc Zhaoqing Guangdong is 6.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.

What is the return on equity of Starlake Bioscience Co Inc Zhaoqing Guangdong (600866)?

The return on equity (ROE) of Starlake Bioscience Co Inc Zhaoqing Guangdong is 5.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of Starlake Bioscience Co Inc Zhaoqing Guangdong (600866)?

On an EBIT basis the return on assets of Starlake Bioscience Co Inc Zhaoqing Guangdong is 8.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

What is the operating margin of Starlake Bioscience Co Inc Zhaoqing Guangdong (600866)?

The operating margin of Starlake Bioscience Co Inc Zhaoqing Guangdong is −1.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.

How fast is revenue growing at Starlake Bioscience Co Inc Zhaoqing Guangdong (600866)?

Revenue at Starlake Bioscience Co Inc Zhaoqing Guangdong is growing −7.4% versus a year earlier (3y avg −3.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.

How fast are earnings growing at Starlake Bioscience Co Inc Zhaoqing Guangdong (600866)?

Earnings per share at Starlake Bioscience Co Inc Zhaoqing Guangdong are growing +4.6% versus a year earlier. How much earnings per share grew versus a year earlier.

How much free cash flow does Starlake Bioscience Co Inc Zhaoqing Guangdong (600866) generate?

The free cash flow of Starlake Bioscience Co Inc Zhaoqing Guangdong is −747M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.

How much net debt does Starlake Bioscience Co Inc Zhaoqing Guangdong (600866) carry?

The net debt of Starlake Bioscience Co Inc Zhaoqing Guangdong is 3.1B CNY (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.

Free · no account needed

Watch Starlake Bioscience Co Inc Zhaoqing Guangdong in the live analysis

One click puts Starlake Bioscience Co Inc Zhaoqing Guangdong on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.